source
- MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine TumorsRoswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.onclive · 3mo ago↗ source
- INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCCFirst-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.onclive · 3mo ago↗ source
- Treatment Intensification Gains Momentum in mCSPC ManagementDuring a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.